Table II.
Univariate and multivariate analysis for progression-free survival.
| Univariate | Multivariate | |||||
|---|---|---|---|---|---|---|
| Variables | HR | 95% CI | P-value | HR | 95% CI | P-value |
| Age | 0.508 | 0.300–0.859 | 0.012a | 0.845 | 0.421–1.695 | 0.635 |
| Sex | 0.869 | 0.546–1.384 | 0.555 | |||
| ECOG PS | ||||||
| 1–2 | ||||||
| 3–4 | 0.220 | 0.130–0.371 | 0.000a | 6.629 | 3.096–14.194 | 0.000a |
| Localization | ||||||
| Frontal | ||||||
| Parietal/temporal | 1.293 | 0.764–2.189 | 0.339 | 1.926 | 1.057–3.510 | 0.032a |
| Occipital | 5.936 | 1.632–21.596 | 0.007a | 3.965 | 0.829–18.950 | 0.084 |
| Other | 3.579 | 1.306–9.807 | 0.013a | 2.320 | 0.782–6.884 | 0.129 |
| Laterality | ||||||
| Right | ||||||
| Left | 0.719 | 0.440–1.173 | 0.187 | |||
| Midline | 1.590 | 0.480–5.261 | 0.448 | |||
| Type of operation | ||||||
| Biopsy | ||||||
| Subtotal | 0.803 | 0.307–2.106 | 0.656 | |||
| Gross total | 0.408 | 0.157–1.064 | 0.067 | |||
| Radiotherapy | ||||||
| Concurrent | ||||||
| Alone | 3.007 | 1.187–7.620 | 0.020a | 4.201 | 1.292–13.657 | 0.017a |
| Temozolamide | ||||||
| Yes | ||||||
| No | 1.366 | 0.706–2.645 | 0.355 | |||
| Second-/third-line systemic therapy | ||||||
| Yes | ||||||
| No | 0.331 | 0.196–0.558 | 0.000a | 0.292 | 0.161–0.527 | 0.000a |
| NLR | ||||||
| >4 | ||||||
| <4 | 1.374 | 0.858–2.202 | 0.186 | |||
| PLR | ||||||
| >135 | ||||||
| <135 | 0.724 | 0.444–1.182 | 0.197 | |||
| Pre-treatment neutrophils | 1.000 | 1.000–1.000 | 0.07 | |||
| Pre-treatment lymphocytes | 1.000 | 1.000–1.001 | 0.236 | |||
| Pre-treatment platelets | 1.000 | 1.000–1.000 | 0.556 | |||
| Pre-treatment NLR | 1.015 | 0.968–1.065 | 0.532 | |||
| Tumour size | 0.993 | 0.972–1.014 | 0.525 | |||
a
Statistically significant. HR, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio.